Media coverage about Genocea Biosciences (NASDAQ:GNCA) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Genocea Biosciences earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.7173452599283 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s rankings:
- Genocea Biosciences (GNCA) Highlights Data from ATLAS Platform at 2018 AACR Meetings (streetinsider.com)
- Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods (finance.yahoo.com)
- Genocea Biosciences (GNCA) Raised to “Buy” at Zacks Investment Research (americanbankingnews.com)
- Head-To-Head Review: Genocea Biosciences (GNCA) & Biogen (BIIB) (americanbankingnews.com)
- Genocea Biosciences (GNCA) Upgraded to “Hold” by ValuEngine (americanbankingnews.com)
Genocea Biosciences stock traded down $0.03 during mid-day trading on Thursday, hitting $0.88. 542,345 shares of the company’s stock were exchanged, compared to its average volume of 1,126,970. The company has a debt-to-equity ratio of -1.26, a current ratio of 0.83 and a quick ratio of 0.83. The company has a market capitalization of $76.57, a price-to-earnings ratio of -0.45 and a beta of 1.21. Genocea Biosciences has a 1-year low of $0.79 and a 1-year high of $7.29.
A number of equities analysts have recently weighed in on GNCA shares. Zacks Investment Research raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday. Cantor Fitzgerald set a $5.00 price target on shares of Genocea Biosciences and gave the stock a “buy” rating in a research note on Sunday, March 11th. HC Wainwright started coverage on shares of Genocea Biosciences in a research note on Thursday, March 8th. They issued a “buy” rating and a $5.00 price target on the stock. Needham & Company LLC raised shares of Genocea Biosciences from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Tuesday, February 6th. Finally, Robert W. Baird started coverage on shares of Genocea Biosciences in a research note on Monday, February 12th. They issued an “outperform” rating and a $3.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $4.41.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections.
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.